A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
Background: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic chara...
| Autores: | , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | INCLIVA |
| Repositorio: | r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| OAI Identifier: | oai:incliva.fundanetsuite.com:p3841 |
| Acceso en línea: | https://incliva.portalinvestigacion.com/publicaciones/3841 |
| Access Level: | acceso abierto |
| Palabra clave: | biologic therapy IL-17 psoriasis secukinumab |
| Sumario: | Background: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. Methods: In this multicenter prospective observational study, we recruited adult patients with moderateto- severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. Results: In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement $ 75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index < 30 kg/cm(2) and patients without previous biologic therapy failures. Limitations: Observational study. Time from onset of psoriasis was not evaluated. Conclusion: Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment. |
|---|